Technetium Tc-99m red blood cells
Identification
- Summary
Technetium Tc-99m red blood cells is a diagnostic radiopharmaceutical agent used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding.
- Generic Name
- Technetium Tc-99m red blood cells
- DrugBank Accession Number
- DB09493
- Background
Technetium Tc-99m red blood cells is a radiopharmaceutical diagnostic agent that is intravenously administered to be used in blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding. It is clinically useful in early detection and localization of bleeding sites, and preoperative diagnosis of hemangioma 4,1. Autologous red blood cells are radiolabeled with sodium pertechnetate Tc 99m in the reaction vial. Radiolabeled red blood cells are re-injected intravenously into the patient for gamma scintigraphic imaging Label. It is suggested that in vitro labelling improves the heart-to-background ratio during imaging 2.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Technetium (99mTc) red blood cells
- Technetium Tc 99m red blood cells
- Technetium Tc 99m-labeled red blood cells
- Technetium Tc-99m red blood cell
- Technetium Tc-99m red blood cell human
Pharmacology
- Indication
Indicated for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Gastrointestinal bleeding •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Technetium Tc-99m red blood cells are diagnostic agents that are distributed within the circulation to assess the vascular nature of hemangiomas and diagnosis of venous occlusion 3. Blood abnormalities can be detected during gamma scintigraphic imaging.
- Mechanism of action
Autologous red blood cells (RBC) are collected from the patient and put into the reaction vial for radiolabeling, followed by anticoagulation with heparin or Anticoagulant Citrate Dextrose Solution (ACD). In the reaction vial, stannous ion diffuses across the RBC membrane and accumulates intracellularly. Sodium hypochlorite, which does not cross the RBC membrane, is then added to the reaction vial to oxidize the extracellular stannous ion. Finally, sodium pertechnetate Tc 99m is added to the oxidized reaction vial to diffuse across the red blood cell membrane and be reduced by the intracellular stannous ion. Upon reduction, Tc 99m cannot diffuse out of the RBC. Technetium Tc 99m-labeled red blood cells are injected again into the patient for gamma scintigraphic imaging Label.
- Absorption
Not Available
- Volume of distribution
Following intravenous injection, the technetium Tc 99m-labeled red blood cells distribute within the blood pool with an estimated volume of distribution of approximately 5.6% of bodyweight Label.
- Protein binding
Of the total technetium Tc 99m retained in the whole blood pool 24 hours after administration, 95% remains bound to the red blood cells Label.
- Metabolism
- Not Available
- Route of elimination
Approximately 25% of the injected dose is excreted in the urine in the first 24 hours Label.
- Half-life
Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. The technetium Tc 99m is well retained in the blood pool with an estimated biological half-life of approximately 29 hours Label.
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility Label.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image UltraTag RBC Kit 0.05 mg/9.5mg Intravenous Mallinckrodt 1991-06-10 2017-07-01 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- D8L75GM22O
- CAS number
- Not Available
References
- General References
- Emslie JT, Zarnegar K, Siegel ME, Beart RW Jr: Technetium-99m-labeled red blood cell scans in the investigation of gastrointestinal bleeding. Dis Colon Rectum. 1996 Jul;39(7):750-4. [Article]
- Patrick ST, Glowniak JV, Turner FE, Robbins MS, Wolfangel RG: Comparison of in vitro RBC labeling with the UltraTag RBC kit versus in vivo labeling. J Nucl Med. 1991 Feb;32(2):242-4. [Article]
- Front D, Israel O, Groshar D, Weininger J: Technetium-99m-labeled red blood cell imaging. Semin Nucl Med. 1984 Jul;14(3):226-50. [Article]
- Polito E, Burroni L, Pichierri P, Loffredo A, Vattimo AG: Technetium tc 99m-labeled red blood cells in the preoperative diagnosis of cavernous hemangioma and other vascular orbital tumors. Arch Ophthalmol. 2005 Dec;123(12):1678-83. doi: 10.1001/archopht.123.12.1678. [Article]
- External Links
- FDA label
- Download (233 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit Intravenous 0.05 mg/9.5mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 19:10 / Updated at February 03, 2022 06:26